Premium
Population pharmacokinetic analysis of axitinib in healthy volunteers
Author(s) -
Garrett May,
Poland Bill,
Brennan Meghan,
Hee Brian,
Pithavala Yazdi K.,
Amantea Michael A.
Publication year - 2014
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12206
Subject(s) - pharmacokinetics , population pharmacokinetics , medicine , axitinib , pharmacology , population , environmental health , cancer , sunitinib
Aims Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 approved for second line treatment of advanced renal cell carcinoma. The objectives of this analysis were to assess plasma pharmacokinetics and identify covariates that may explain variability in axitinib disposition following single dose administration in healthy volunteers. Methods Plasma concentration–time data from 337 healthy volunteers in 10 phase I studies were analyzed, using non‐linear mixed effects modelling ( nonmem ) to estimate population pharmacokinetic parameters and evaluate relationships between parameters and food, formulation, demographic factors, measures of renal and hepatic function and metabolic genotypes ( UGT1A1*28 and CYP2C19 ). Results A two compartment structural model with first order absorption and lag time best described axitinib pharmacokinetics. Population estimates for systemic clearance ( CL ), central volume of distribution ( V c ), absorption rate constant ( k a ) and absolute bioavailability ( F ) were 17.0 l h −1 , 45.3 l, 0.523 h −1 and 46.5%, respectively. With axitinib Form IV , k a and F increased in the fasted state by 207% and 33.8%, respectively. For Form XLI (marketed formulation), F was 15% lower compared with Form IV . CL was not significantly influenced by any of the covariates studied. Body weight significantly affected V c , but the effect was within the estimated interindividual variability for V c . Conclusions The analysis established a model that adequately characterizes axitinib pharmacokinetics in healthy volunteers. V c was found to increase with body weight. However, no change in plasma exposures is expected with change in body weight; hence no dose adjustment is warranted.